Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease

Next Previous
Trial Profile

The impact of DPP-4 inhibitor on daily glucose profile and coronary plaque character in impaired glucose tolerance patients with coronary artery disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Glucose intolerance
  • Focus Pharmacodynamics
  • Acronyms VOGUE-KOBE

Most Recent Events

  • 15 Mar 2022 According to UMIN, date of closure to data entry is 31 Mar 2019, date of trial data considered complete is 31 Mar 2019 and date of analysis conclusion is 31 Mar 2019.
  • 15 Mar 2022 Status changed from recruiting to completed.
  • 11 Sep 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top